ArticleJournal of medical case reports2025
Successful treatment of chronic spontaneous urticaria and bladder pain syndrome with montelukast and/or omalizumab: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder pain syndrome (BPS) is a chronic condition characterized by pelvic pain, frequency, and urgency lasting more than 6 months without a urinary tract infection. It is a devastating condition that affects both sexes and is often confused with other conditions that cause pelvic pain. Diagnosis is difficult, and effective treatment options are limited. CASE PRESENTATION: In this article, I present a 59 year-old Turkish male patient with chronic spontaneous urticaria with typical clinical symptoms of bladder pain syndrome. Common etiologies that could cause increased urinary frequency, urgency or nocturia, urinary tract infection, and overactive bladder were excluded.
conclusionThe patient's symptoms improved significantly with omalizumab and montelukast. This case not only provides new insight into the management of BPS, but also highlights the potential roles of mast cell-mediated mechanisms in the etiology and treatment of this complex condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.